PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19891980-9	2010	The number of carrageenan-induced Fos-like immunoreactive profiles was less in rosiglitazone-treated rats as compared to vehicle controls.	Rosiglitazone	79-92	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	34-37	
18583263-1	2008	OBJECTIVE: To investigate the mechanism of rosiglitazone (RSG, the activator of peroxisome proliferators activated receptor lambda) for inhibiting endothelin-1 (ET-1)-induced neonatal rat cardiac myocyte hypertrophy and the role of protein kinase C (PKC) and c-fos.	Rosiglitazone	43-56	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	259-264	
18583263-1	2008	OBJECTIVE: To investigate the mechanism of rosiglitazone (RSG, the activator of peroxisome proliferators activated receptor lambda) for inhibiting endothelin-1 (ET-1)-induced neonatal rat cardiac myocyte hypertrophy and the role of protein kinase C (PKC) and c-fos.	Rosiglitazone	58-61	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	259-264	
18583263-7	2008	RSG inhibited protein synthesis enhancement and increased (3)H-leucine incorporation induced by ET-1 and PMA, and antagonized the effects of ET-1 and PMA in promoting PKC activity and c-fos protein expression in the myocytes.	Rosiglitazone	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	184-189	
18583263-8	2008	CONCLUSION: The inhibitory effect of RSG on ET-1- or PMA-induced myocyte hypertrophy is associated with PKC-c-fos pathway.	Rosiglitazone	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	108-113